Advertisement
Doug Mowen, managing director and leader of PricewaterhouseCoopers' Medical Device practice, will present "Device Innovation Scorecard: Comparing Global Innovation Factors in Selected Countries Relevant to Medical Device Companies" during the closing keynote address on May 5. The presentation will include top line findings of PricewaterhouseCoopers' independent analysis of key factors that create access to or barriers for medical device innovation in nine markets: Brazil, China, France, Germany, Israel, India, Japan, United Kingdom and the United States.
Advertisement
The presentation will include an Innovation Scorecard of the characteristics in each of the markets as well as a comparison across multiple markets. The Innovation Scorecard is based on rigorous, proprietary methodology, developed by PricewaterhouseCoopers, using approximately 100 key metrics to determine a score for each of the following four areas:
PricewaterhouseCoopers conducted the independent study to help its clients, patient advocacy groups, regulators, ministers of health and other government and health industry leaders to better understand the ability of patients to access innovative medical technology in their own territories, the opportunities for economic development as well as product development, manufacturing and commercial market opportunities for medical device companies seeking to expand both domestically and internationally.
The 2010 International Medical Device Industry Compliance Congress is co-sponsored by 14 global medical technology associations. The annual meeting brings together medical device industry executives, compliance and legal officers from both small and large medical technology manufacturers from across the globe.
About PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group
PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group (www.pwc.com/medtech) provides clients with audit, tax and advisory services. The firm has extensive experience in delivering industry-tailored solutions on a wide range of strategic, financial and operational issues. The Pharmaceutical and Life Sciences Industry Group is part of PricewaterhouseCoopers' larger initiative for the health-related industries that brings together expertise and allows collaboration across all sectors in the health continuum.
About PricewaterhouseCoopers
PricewaterhouseCoopers (www.pwc.com) provides industry-focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders. More than 163,000 people in 151 countries across our network share their thinking, experience and solutions to develop fresh perspectives and practical advice.
"PricewaterhouseCoopers" refers to the network of member firms of PricewaterhouseCoopers International Limited, each of which is a separate and independent legal entity.
© 2010 PricewaterhouseCoopers LLP. All rights reserved
1. The over-all regulatory environment, including the regulatory approval process and reimbursement methodologies. 2. Access, including patient access to care delivery, the availability of adequate healthcare infrastructure and medical staff, technology infrastructure and penetration of Internet and mobile technologies. 3. Demographics, including key population health measures, disease and risk factors as well as innovation workforce demographics such as the availability of scientists, engineers. 4. Market factors, including the availability of public and private investment, R&D expenditures, the level of collaboration between companies and academia, and the historical track record of medical technology in the market.
SOURCE PricewaterhouseCoopers
